Amanote Research
Register
Sign In
Pms20 - Budget Impact of Introducing Secukinumab in the Treatment of Ankylosing Spondylitis From the Private Payer Perspective in Brazil
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.1734
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
C. Tozato
C. Huerta
C. Suzuki
N. Lopes
Publisher
Elsevier BV
Related search
Pms42 - Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy50 - Budget-Impact Analysis (Bia) of Chronic Pain Syndromes From a Healthcare Payer Perspective in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms29 - Secukinumab Versus Adalimumab in the Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis Among 52 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Correction To: Secukinumab: A Review in Ankylosing Spondylitis
Drugs
Pharmacology
The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond
Expert Review of Clinical Immunology
Allergy
Immunology
Estimating the Financial Impact of Introducing Glycopyrronium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease (Copd) From the Perspective of Public Payer of São Paulo (Sp) – Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms31 - Secukinumab as a More Eeficient Alternative for Ankylosing Spondylitis Treatment: A Cost Per Responder Analysis From Korean Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
